companies / pathos-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 500,000,000500.0M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Cambridge, USA | |
| industry | unknown | |
| stage | series-b+ |
Pathos AI applies machine learning to drug development, using clinical and multi-omics data to design adaptive trials and identify responder populations. Pharma and biotech partners license the Pathos platform to accelerate Phase 2/3 trials. The company runs collaborative drug-development partnerships rather than only selling software.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-05-15 | series-d+ | 365,000,000365.0M | null | ○ |
Nginx, React 16.13.1, reCAPTCHA, styled-components, parallax.js, PHP, Duda, jquery 3.7.0, friendly-challenge 0.9.8
| fact | status | src |
|---|---|---|
| Series D+, $365.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |